The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model

Blood

Volumn 121, Issue 17, 2013, Pages 3447-3458

  Sportoletti, Paolo ^a   Varasano, Emanuela ^a   Rossi, Roberta ^a   Bereshchenko, Oxana ^a   Cecchini, Debora ^a   Gionfriddo, Ilaria ^a   Bolli, Niccolò ^a   Tiacci, Enrico ^a   Intermesoli, Tamara ^b   Zanghì, Pamela ^b   Masciulli, Arianna ^c   Martelli, Maria Paola ^a   Falzetti, Franca ^a   Martelli, Massimo F ^a   Falini, Brunangelo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c Santa Maria Imbaro   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; MESSENGER RNA; MICRORNA 10A; MICRORNA 10B; MICRORNA 20A; NUCLEOLIN; NUCLEOPHOSMIN; THROMBOPOIETIN; UNCLASSIFIED DRUG; CRE RECOMBINASE; INTEGRASE; MICRORNA; NUCLEAR PROTEIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL SEPARATION; CONTROLLED STUDY; CYTOPLASM; EMBRYO DEVELOPMENT; FOLLOW UP; GENE MUTATION; GENOTYPE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HOMOLOGOUS RECOMBINATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PLATELET DISTRIBUTION WIDTH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; UPREGULATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL PROLIFERATION; CLONOGENIC ASSAY; DISEASE MODEL; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPOIESIS; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRASES; LEUKEMIA, MYELOID, ACUTE; MEGAKARYOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; MUTATION; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOPOIESIS;

MLCS; MLOWN;

EID: 84879400790     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-449553     Document Type: Article

References (50)

1. Falini B, Mecucci C, Tiacci E, et al; GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-266.
2. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92(4):519-532.
3. Schlenk RF, Döhner K, Krauter J, et al; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918.
4. Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024-3032.
5. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc1 AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899-902.
6. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
7. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA. 2008; 105(10):3945-3950.
8. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111(10):5078-5085.
9. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596-604.
10. Russ AC, Sander S, Lück SC, et al. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. Haematologica. 2011; 96(12):1783-1791.
11. Martelli MP, Pettirossi V, Thiede C, et al. CD341 cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010;116(19):3907-3922.
12. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109-1120.
13. Arber DA, Brunning RD, Le Beau MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008:110-123.
14. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56(3):379-390.
15. Cordell JL, Pulford KA, Bigerna B, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood. 1999;93(2):632-642.
16. Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc1 AML. Blood. 2006;107(11):4514-4523.
17. Bolli N, Nicoletti I, De Marco MF, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res. 2007;67(13):6230-6237.
18. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, Nicoletti I. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23(10):1731-1743.
19. Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108(6):1999-2005.
20. Bolli N, De Marco MF, Martelli MP, et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia. 2009;23(3):501-509.
21. Colombo E, Martinelli P, Zamponi R, et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 2006;66(6):3044-3050.
22. Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 2008;182(1):19-26.
23. Leong SM, Tan BX, Bte Ahmad B, et al. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood. 2010;116(17):3286-3296.
24. Cheng K, Sportoletti P, Ito K, Clohessy JG, Teruya-Feldstein J, Kutok JL, Pandolfi PP. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood. 2010;115(16):3341-3345.
25. Bolli N, Payne EM, Grabher C, et al. Expression of the cytoplasmic NPM1 mutant (NPMc1) causes the expansion of hematopoietic cells in zebrafish. Blood. 2010;115(16):3329-3340.
26. Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011;43(5):470-475.
27. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. ‘Green mice’ as a source of ubiquitous green cells. FEBS Lett. 1997;407(3):313-319.
28. Lakso M, Sauer B, Mosinger B Jr, et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA. 1992;89(14):6232-6236.
29. Martelli MP, Manes N, Liso A, et al. A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. Leukemia. 2008;22(12):2285-2288.
30. Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005;19(10):1760-1767.
31. Pronk CJ, Rossi DJ, Månsson R, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428-442.
32. Facchetti F, Chan JK, Zhang W, et al. Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathological conditions. Am J Pathol. 1999;154(4):1037-1046.
33. Sola-Visner MC, Christensen RD, Hutson AD, Rimsza LM. Megakaryocyte size and concentration in the bone marrow of thrombocytopenic and nonthrombocytopenic neonates. Pediatr Res. 2007;61(4):479-484.
34. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995; 269(5229):1427-1429.
35. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103-1108.
36. Zhang J, Varas F, Stadtfeld M, Heck S, Faust N, Graf T. CD41-YFP mice allow in vivo labeling of megakaryocytic cells and reveal a subset of platelets hyperreactive to thrombin stimulation. Exp Hematol. 2007;35(3):490-499.
37. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA. 2006;103(13):5078-5083.
38. Opalinska JB, Bersenev A, Zhang Z, et al. MicroRNA expression in maturing murine megakaryocytes. Blood. 2010;116(23):e128-e138.
39. Mansfield JH, Harfe BD, Nissen R, et al. MicroRNA-responsive ‘sensor’ transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression. Nat Genet. 2004;36(10):1079-1083.
40. Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P, Pandolfi PP. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene. 2007;26(53):7391-7400.
41. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood. 2006;108(13):4146-4155.
42. Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010;115(18):3776-3786.
43. Tanzer A, Amemiya CT, Kim CB, Stadler PF. Evolution of microRNAs located within Hox gene clusters. J Exp Zoolog B Mol Dev Evol. 2005; 304(1):75-85.
44. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6(7):493-505.
45. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38(20): 7248-7259.
46. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719-724.
47. Gilliland DG. Hematologic malignancies. Curr Opin Hematol. 2001;8(4):189-191.
48. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol. 2009;21(6): 573-581.
49. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-486.
50. Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011;4:36.